Given its glucose-lowering properties, some studies have found that the adjuvant use of HCQ can significantly help control blood glucose in T2DM patients who are already using two to three antidiabetic medications that did not provide adequate control [17–19]. Additionally, Wasko et al. found that HCQ at a dose of 400 mg/day can increase the plasma levels of adiponectin [16]; through its anti-inflammatory effects, adiponectin plays a key role in insulin resistance and metabolic syndrome development by enhancing insulin sensitivity [20–22]. This evidence concerns the gene ADIPOQ and Insulin resistance.